- Home
- MOBX vs STTK Comparison
MOBX vs STTK Comparison
Compare MOBX & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOBX
- STTK
- Stock Information
- Founded
- MOBX 2020
- STTK 2016
- Country
- MOBX United States
- STTK United States
- Employees
- MOBX N/A
- STTK N/A
- Industry
- MOBX
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- MOBX
- STTK Health Care
- Exchange
- MOBX Nasdaq
- STTK Nasdaq
- Market Cap
- MOBX 41.3M
- STTK 37.6M
- IPO Year
- MOBX N/A
- STTK 2020
- Fundamental
- Price
- MOBX $0.69
- STTK $1.14
- Analyst Decision
- MOBX
- STTK Hold
- Analyst Count
- MOBX 0
- STTK 4
- Target Price
- MOBX N/A
- STTK $3.00
- AVG Volume (30 Days)
- MOBX 163.5K
- STTK 98.3K
- Earning Date
- MOBX 05-15-2025
- STTK 05-01-2025
- Dividend Yield
- MOBX N/A
- STTK N/A
- EPS Growth
- MOBX N/A
- STTK N/A
- EPS
- MOBX N/A
- STTK N/A
- Revenue
- MOBX $10,692,000.00
- STTK $4,606,000.00
- Revenue This Year
- MOBX N/A
- STTK N/A
- Revenue Next Year
- MOBX N/A
- STTK N/A
- P/E Ratio
- MOBX N/A
- STTK N/A
- Revenue Growth
- MOBX 450.28
- STTK 69.65
- 52 Week Low
- MOBX $0.55
- STTK $0.69
- 52 Week High
- MOBX $2.47
- STTK $7.49
- Technical
- Relative Strength Index (RSI)
- MOBX 43.78
- STTK 53.12
- Support Level
- MOBX $0.67
- STTK $0.98
- Resistance Level
- MOBX $0.73
- STTK $1.13
- Average True Range (ATR)
- MOBX 0.07
- STTK 0.10
- MACD
- MOBX -0.00
- STTK 0.00
- Stochastic Oscillator
- MOBX 35.28
- STTK 54.55
About MOBX Mobix Labs Inc.
Mobix Labs Inc. specializes in designing, developing, and selling components and systems for wireless and wired connectivity, radio frequency (RF) technologies, switching, and electromagnetic interference (EMI) filtering solutions. The company serves markets, including commercial, industrial, automotive, medical, aerospace, defense, and others.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.